immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.
Company profile
Ticker
IBRX
Exchange
Website
CEO
Patrick Soon-Shiong
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Conkwest, Inc., NantKwest, Inc., ZelleRx Corp
SEC CIK
Corporate docs
Subsidiaries
Infacell Therapeutics, Inc. • Inex Bio, Inc. • NantCell, Inc. • Etubics Corporation • Altor BioScience, LLC • Altor BioScience Manufacturing Company, LLC • Receptome, Inc. • VBC Holdings LLC • GlobeImmune, Inc. • Immunotherapy NANTibody, LLC ...
IBRX stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
17 Apr 24
S-3
Shelf registration
28 Mar 24
10-K
2023 FY
Annual report
19 Mar 24
8-K
Departure of Directors or Certain Officers
23 Feb 24
8-K
ImmunityBio Announces $320 Million Investment by Oberland
2 Jan 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
DEF 14C
Information statement
28 Sep 23
D
$469.99 mm in equity / debt, sold $469.99 mm, 3 investors
22 Sep 23
PRE 14C
Preliminary information
15 Sep 23
8-K
ImmunityBio Announces $470 Million Equity and Debt Financing
11 Sep 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 177.96 mm | 177.96 mm | 177.96 mm | 177.96 mm | 177.96 mm | 177.96 mm |
Cash burn (monthly) | (no burn) | (no burn) | 31.88 mm | 38.23 mm | 29.13 mm | 28.52 mm |
Cash used (since last report) | n/a | n/a | 211.81 mm | 253.97 mm | 193.56 mm | 189.46 mm |
Cash remaining | n/a | n/a | -33.84 mm | -76.01 mm | -15.60 mm | -11.50 mm |
Runway (months of cash) | n/a | n/a | -1.1 | -2.0 | -0.5 | -0.4 |
Institutional ownership, Q3 2023
46.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 133 |
Opened positions | 29 |
Closed positions | 14 |
Increased positions | 33 |
Reduced positions | 29 |
13F shares | Current |
---|---|
Total value | 83.75 bn |
Total shares | 311.30 mm |
Total puts | 1.23 mm |
Total calls | 941.30 k |
Total put/call ratio | 1.3 |
Largest owners | Shares | Value |
---|---|---|
Cambridge Equities | 261.71 mm | $403.03 mm |
Vanguard | 14.68 mm | $24.80 bn |
BLK Blackrock | 10.81 mm | $18.27 bn |
Armistice Capital | 3.48 mm | $5.87 bn |
Geode Capital Management | 2.81 mm | $4.74 bn |
STT State Street | 2.72 mm | $4.60 bn |
Credit Suisse | 1.53 mm | $2.59 bn |
JPM JPMorgan Chase & Co. | 1.45 mm | $2.45 bn |
NTRS Northern Trust | 1.15 mm | $1.95 bn |
Charles Schwab Investment Management | 1.05 mm | $1.77 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Feb 24 | Simon Barry J. | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 159,146 | 833.93 k | 159,146 |
22 Feb 24 | Simon Barry J. | RSU Common Stock | Grant | Acquire A | No | No | 0 | 45,731 | 0.00 | 45,731 |
22 Feb 24 | Regan J Lauer | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 42,439 | 222.38 k | 42,439 |
22 Feb 24 | Regan J Lauer | RSU Common Stock | Grant | Acquire A | No | No | 0 | 12,195 | 0.00 | 12,195 |
22 Feb 24 | David C. Sachs | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 424,390 | 2.22 mm | 424,390 |
22 Feb 24 | David C. Sachs | RSU Common Stock | Grant | Acquire A | No | No | 0 | 121,951 | 0.00 | 121,951 |
22 Feb 24 | Richard Adcock | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 1,591,463 | 8.34 mm | 1,591,463 |
22 Feb 24 | Richard Adcock | RSU Common Stock | Grant | Acquire A | No | No | 0 | 457,317 | 0.00 | 457,317 |
22 Feb 24 | Soon-shiong Patrick | Stock Option Common Stock | Grant | Acquire A | No | No | 5.24 | 1,193,597 | 6.25 mm | 1,193,597 |
22 Feb 24 | Soon-shiong Patrick | RSU Common Stock | Grant | Acquire A | No | No | 0 | 342,987 | 0.00 | 342,987 |
News
Piper Sandler Maintains Neutral on ImmunityBio, Raises Price Target to $5
25 Mar 24
10 Health Care Stocks With Whale Alerts In Today's Session
20 Mar 24
Sportradar Group Posts Upbeat Earnings, Joins Kingsoft Cloud, Braskem And Other Big Stocks Moving Higher On Wednesday
20 Mar 24
ImmunityBio: Q4 Earnings Insights
19 Mar 24
Immunitybio Announced Data From Phase 1 Pilot Study Showed N-803 Combined With Natural Killer Cells Could Reduce Viral Load In People Living With HIV
5 Mar 24
Press releases
Biotech's Role in Addressing the Pancreatic Cancer Emergency
14 Mar 24
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
6 Mar 24
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
5 Mar 24
Biotech With Potential: Coeptis Therapeutics (COEP) And 3 Underrated Gems
21 Feb 24
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
21 Feb 24